University of Perugia - Urology and Andrology, Perugia, Italy.
University of Padua - Oncological and Surgical Sciences, Urology Clinic, Padua; University of Brescia - Urology, Brescia; University of Florence - Urology, Florence; University of Genova - Urology, Genova; University of Torino - Urology, Torino; University Federico II - Urology, Naples; University of Verona - Urology, Verona; Vita-Salute University - Urology, San Raffaele, Milan; University of Bologna - Urology, Bologna; University of Trieste - Urology, Trieste; University of Eastern Piedimont - Urology, Novara, Italy.
Study Type - Prognosis cohort series (multi-centre) Level of Evidence 2b.
What's known on the subject? and What does the study add? The relatively low prevalence of papillary RCC and the limited number of patients enrolled in most of the surgical series limit meaningful conclusions with respect to cancer-related outcome and independent prognostic information. Patients with papillary RCC have relatively a low risk of tumour recurrence and cancer-related death after surgery. Pathological lymph node stage, presence of metastases and Fuhrman nuclear grade were the main independent predictors of cancer-related outcomes, whereas only a non-statistically significant trend was found for the 2009 pathological T stage.
To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC.
From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surgery.
At a median (interquartile range) follow-up of 39.2 (21.7-72) months, 81 (14%) patients had experienced disease progression and 63 (11%) patients had died from disease; the 5-year RFS estimate was 85.5%. In multivariable analysis, pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.9; P= 0.007) and Fuhrman nuclear grade (pooled P= 0.039) were all independent predictors of RFS; the 5-year CSS estimate was 87.9%. In Cox multivariable analysis, an independent predictive role was reconfirmed for mode of presentation (pooled P= 0.038), pathological N stage (pooled P < 0.001), M stage (hazard ratio, 2.4; P= 0.049) and Fuhrman nuclear grade (pooled P= 0.037).
Patients with pRCC have a low risk of tumour recurrence and cancer-related death after surgery. Fuhrman nuclear grade was found to be a stronger predictor of both RFS and CSS, whereas only a non-statistically significant trend was found for the 2009 pathological T stage.
Written by:
Zucchi A, Novara G, Costantini E, Antonelli A, Carini M, Carmignani G, Cosciani Cunico S, Fontana D, Longo N, Martignoni G, Minervini A, Mirone V, Porena M, Roscigno M, Schiavina R, Simeone C, Simonato A, Siracusano S, Terrone C, Ficarra V. Are you the author?
Reference: BJU Int. 2011 Aug 22. Epub ahead of print.
doi: 10.1111/j.1464-410X.2011.10517.x
PubMed Abstract
PMID: 21871053
UroToday.com Renal Cancer Section
